Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2794-2800

  Stresemann, Carlo ^a   Brueckner, Bodo ^a   Musch, Tanja ^a   Stopper, Helga ^b   Lyko, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; PROCAINE; RECOMBINANT ENZYME; RG 108; UNCLASSIFIED DRUG; ZEBULARINE;

ARTICLE; CANCER CELL CULTURE; CELL FREE SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; GENETIC COMPLEMENTATION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICRONUCLEUS; PRIORITY JOURNAL;

AZACITIDINE; CATECHIN; CELL LINE, TUMOR; CYTIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; HUMANS; INDOLES; JURKAT CELLS; PROCAINE; PROPIONIC ACIDS;

EID: 33645086120     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2821     Document Type: Article

References (44)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415-28.
3. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4:351-8.
4. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
5. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2004;74:481-514.
6. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
7. Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004;25:551-4.
8. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
9. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984;81:6993-7.
10. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group b. J Clin Oncol 2002;20: 2429-40.
11. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974;30:405-22.
12. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-beta-d-arabinofuranosylcytosine and 5-azacytidine against 11210 leukemia. Leuk Res 1984;8: 1043-9.
13. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase ii study in elderly patients. J Clin Oncol 2000;18:956-62.
14. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103: 1635-40.
15. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56.
16. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321:591-9.
17. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
18. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6:151-8.
19. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801.
20. Robert MF, Morin S, Beaulieu N, et al. Dnmtl is required to maintain cpg methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-5.
21. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003;63:4984-9.
22. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70.
23. Brueckner B, Boy RG, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305-11.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
25. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
26. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
27. Stach D, Schmitz OJ, Stilgenbauer S, et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003;31:e2.
28. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
29. Xiong Z, Laird PW. Cobra: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25: 2532-4.
30. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005;23:3906-11.
31. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase i and pharmacokinetic study of 5-aza-2′-deoxycytidine (nsc 127716) in cancer patients. Cancer Res 1986;46:4831-6.
32. Holleran JL, Parise RA, Joseph E, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005;11:3862-8.
33. Chow HH, Cai Y, Alberts DS, et al. Phase i pharmacokinetic study of tea polyplienols following single-dose administration of epigallocatechin gallate and polyphenone. Cancer Epidemiol Biomarkers Prev 2001;10:53-8.
34. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
35. Flynn J, Fang JY, Mikovits JA, Reich NO. A potent cell-active allosteric inhibitor of murine DNA cytosine c5 methyltransferase. J Biol Chem 2003;278:8238-43.
36. Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis 1998;19:597-604.
37. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and proeainamide and their potential use in cancer therapy. Clin Cancer Res 2003;9:1596-603.
38. Lyko F, Brown R. DNA methyltransferase inhibitors and the establishment of epigenetic cancer therapies. J Natl Cancer Inst 2005;97:1498-506.
39. Elbling L, Weiss RM, Teufelhofer U, et al. Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. Faseb J 2005;19:807-9.
40. Guttenbach M, Schmid M. Exclusion of specific human chromosomes into micronuclei by 5-azacytidinc treatment of lymphocyte cultures. Exp Cell Res 1994;211: 127-32.
41. Stopper H, Korber C, Gibis P, Spencer DL, Caspary WJ. Micronuclei induced by modulators of methylation: analogs of 5-azacytidine. Carcinogenesis 1995;16: 1647-50.
42. Chuang JC, Yoo CB, Kwan JM, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 2005;4:1515-20.
43. Nakagawa H, Hasumi K, Woo JT, Nagai K, Wachi M. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis 2004;25:1567-74.
44. Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, Esteller M, Serrano M. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′ -deoxycytidine. Oncogene 2004;23:735-43.